Abstract:Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and malignant neoplasm. The aberrant expression of miR-135b-5p and secreted frizzled-related protein 4 (SFRP4) has been revealed to be involved in various cancers. However, the clinical significance of miR-135b-5p and that of its potential target SFRP4 in PDAC remain to be elucidated. Here, we found that miR-135b-5p was markedly upregulated in pancreatic cancer tissue compared with corresponding adjacent normal tissue, whereas SFRP4 was significantly downregulated. The expression of miR-135b-5p was negatively correlated with the expression of SFRP4. PDAC patients with regional lymph node metastases, vascular invasion, tumor microthrombus and higher PET-CT SUVmax values had significantly higher expression of miR-135b-5p. Immunoblotting revealed that regional lymph node metastases were correlated with expressive states of SFRP4. Negative SFRP4 expression was significantly associated with old age, larger tumor size, regional lymph node metastasis and poor differentiation. Survival analyses demonstrated that miR-135b-5p and SFRP4 could predict outcomes and that miR-135b-5p was an independent predictor. In vitro, the overexpression of miR-135b-5p promoted the migration and proliferation of PANC-1 and MiaPaCa-2 cells, while immunoblotting demonstrated the downregulation of SFRP4 and the upregulation of beta-catenin. Inhibition of miR-135b-5p suppressed migration, induced apoptosis of PANC-1 and AsPC-1 cells, and reduced the expression of beta-catenin. A luciferase reporter assay confirmed that miR-135b-5p repressed the expression of SFRP4 via the direct targeting of its 3'-untranslated regions. In conclusion, the overexpression of miR-135b-5p and the downregulation of SFRP4 were associated with unfavorable clinical characteristics and poor prognosis, and SFRP4 was shown to be a direct downstream target of miR-135b-5p. Thus, the mechanism that underlies the miR-135b-5p-SFRP4-Wnt/beta-catenin axis represents a potential target for PDAC diagnosis and therapy.

Figure S4 from Lncrna THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome Via Sponging Mir-484 and Interacting with YAP

Figure S3 from Lncrna THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome Via Sponging Mir-484 and Interacting with YAP

Figure S2 from Lncrna &Lt;i>thap9-As1</i> Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome Via Sponging Mir-484 and Interacting with YAP

Figure S1 from Lncrna THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome Via Sponging Mir-484 and Interacting with YAP

Long Non-Coding RNA DSCAM-AS1 Promotes Pancreatic Cancer Progression Via Regulating the Mir-136-5p/pbx3 Axis

Hsa_circ_0014784-induced YAP1 promoted the progression of pancreatic cancer by sponging miR-214-3p

Supplementary Figures S1-S4 from YAP Promotes Malignant Progression of <i>Lkb1</i>-Deficient Lung Adenocarcinoma through Downstream Regulation of Survivin

LINC01559 accelerates pancreatic cancer cell proliferation and migration through YAP-mediated pathway.

The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.

Pseudogene AK4P1 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Relieving Mir-375-mediated YAP1 Degradation.

LncRNA LINC01857 drives pancreatic adenocarcinoma progression via modulating miR-19a-3p/SMOC2

Supplementary Fig 2 from YAP Suppresses Lung Squamous Cell Carcinoma Progression Via Deregulation of the DNp63–GPX2 Axis and ROS Accumulation

A phosphatidic acid-binding lncRNA SNHG9 facilitates LATS1 liquid–liquid phase separation to promote oncogenic YAP signaling

Inhibiting YAP Expression Suppresses Pancreatic Cancer Progression by Disrupting Tumor-Stromal Interactions

Yap Promotes Malignant Progression of Lkb1-Deficient Lung Adenocarcinoma Through Downstream Regulation of Survivin

Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer

Overexpression of Mir-135b-5p Promotes Unfavorable Clinical Characteristics and Poor Prognosis Via the Repression of Sfrp4 in Pancreatic Cancer

MicroRNA-138 Acts As a Tumor Suppressor in Non Small Cell Lung Cancer Via Targeting YAP1

High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma

Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3

THAP7 Promotes Cell Proliferation by Regulating the G1/S Phase Transition Via Epigenetically Silencing P21 in Lung Adenocarcinoma